Nivolumab + Relatlimab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Nov 10, 2020 → Jan 4, 2026
NCT ID
NCT04552223About Nivolumab + Relatlimab
Nivolumab + Relatlimab is a phase 2 stage product being developed by Bristol Myers Squibb for Metastatic Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04552223. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07459543 | Approved | Recruiting |
| NCT06237920 | Phase 2 | Recruiting |
| NCT04658147 | Phase 1 | Active |
| NCT04567615 | Phase 2 | Completed |
| NCT04552223 | Phase 2 | Completed |
| NCT03623854 | Phase 2 | Completed |
| NCT03610711 | Phase 1/2 | Active |
| NCT03642067 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Uveal Melanoma